Haleon plc: history, ownership, mission, how it works & makes money

Born as a carve-out from GSK on 18 July 2022, Haleon plc has rapidly established itself as a FTSE 100 consumer-health leader headquartered in Weybridge with a secondary NYSE listing, tracing roots to the 2019 GSK-Pfizer consumer-health merger and evolving through major ownership moves - GSK exiting in May 2024 and Pfizer completing its sale in March 2025 for about £2.5 billion ($3.24 billion) - leaving institutional investors like BlackRock as the largest shareholder (>5%); the company now sits on a market cap of roughly £40.3 billion (Dec 2025) and generated £11.2 billion of revenue in 2024 with Oral Health 29% and VMS 15% contributions, driven by nine power brands including Sensodyne, Panadol, Advil, Centrum and Otrivin, a global footprint across >90 countries, ~24,000 employees, a decentralized regional operating model, R&D centered in Richmond, Virginia, plans to close Maidenhead by 2026 and shift production to Slovakia, commitments to make all packaging recycle-ready by 2025 (70% already compliant) and to empower 50 million people annually (over 41 million reached in 2023), a 7.3% OTC market share in 2022 and targets of high single-digit profit growth from 2026 alongside £800 million of planned productivity savings and a 30% annual working-capital reduction to fuel further expansion and innovation.

Haleon plc (HLN.L): Intro

• Spin‑off date: 18 July 2022 (from GSK)
• Headquarters: Weybridge, England
• Primary listing: London Stock Exchange (FTSE 100); secondary listing: NYSE
• Largest current shareholder (post‑divestitures): BlackRock Investment Management (UK) Ltd - holding over 5%

• 2019: GSK and Pfizer combined consumer healthcare businesses (GSK ~68%, Pfizer ~32%), creating the asset base that became Haleon.
• 18 Jul 2022: Haleon launched as an independent, publicly listed company when spun off from GSK.
• May 2024: GSK completed disposal of its entire stake in Haleon.
• Mar 2025: Pfizer completed sale of its Haleon stake for ~£2.5bn ($3.24bn), exiting ownership.
• Post‑2025: Institutional investors (e.g., BlackRock) emerged as largest shareholders; company remains a global OTC leader.

• Core revenue from sales of OTC and consumer healthcare products across retail, pharmacy and digital channels.
• Major product categories: oral health, pain relief & topical analgesics, respiratory care, digestive health, and vitamins & supplements.
• Revenue drivers: brand equity (market‑leading global brands), geographic mix (developed markets + faster growth in emerging markets), new product innovation, pricing strategies, and trade/retailer relationships.
• Margins supported by scale, global supply chain optimization, and marketing efficiencies following the spin‑off.
• Channel mix includes brick‑and‑mortar pharmacies, supermarkets, e‑commerce and prescriptions/clinician recommendations where applicable.

• Oral health: Sensodyne (global toothpaste for sensitive teeth)
• Pain relief / topical analgesics: Voltaren; common analgesics such as Panadol/acetaminophen in some markets
• Vitamins & supplements: Centrum multivitamins
• Respiratory & cold care and digestive products across multiple global brands

• Spin‑off date: 18 July 2022
• Pfizer sale of stake: ~£2.5 billion (~$3.24 billion) - March 2025
• GSK stake: disposed in May 2024 (ownership reduced to zero)
• Major institutional holding: BlackRock Investment Management (UK) Ltd - >5% stake

Haleon plc (HLN.L): History

• IPO / Listing: July 2022 - primary listing on the London Stock Exchange; component of the FTSE 100.
• Secondary listing: New York Stock Exchange (ADS) to attract US investors.
• Core categories: oral health, pain relief, respiratory, vitamins & supplements.

• Largest shareholder (Mar 2025): BlackRock Investment Management (UK) Ltd - >5% stake.
• GSK: Sold entire stake in May 2024 - ownership reduced to 0%.
• Pfizer: Sold entire stake in Mar 2025 for ~£2.5 billion (≈ $3.24 billion) - complete exit.
• Shareholder base: diverse mix of institutional investors, asset managers, pension funds and retail holders across UK, US and Europe.

• Revenue drivers: branded OTC sales (oral care, analgesics, vitamins) through retail, pharmacy and e-commerce channels.
• Margins: benefits from scale brands and marketing efficiency; focus on cost savings and price/mix improvements to expand underlying operating margin.
• Geographic mix: significant exposure to North America, Europe, Asia-Pacific, with growing contribution from emerging markets.
• Cash deployment: dividends, bolt-on M&A, and debt management to support capital structure.

Haleon plc (HLN.L): Ownership Structure

• Mission and values: deliver better everyday health with humanity; emphasize consumer empowerment and trust.
• Sustainability target: all product packaging recycle-ready by 2025; 70% of packaging already meets this standard.
• Health inclusivity goal: empower 50 million people annually by 2025; 41+ million people empowered in 2023.
• R&D focus: sustained investment to drive innovation across OTC medicines, oral health, vitamins and supplements.
• Diversity & inclusion: culture-building to reflect global communities and foster inclusive practices.

• How it works / makes money: sells branded over‑the‑counter medicines and health products through retail, pharmacy and e‑commerce channels worldwide, supported by brand marketing, R&D-driven product innovation and supply chain scale.
• Trust & governance: emphasizes product quality, safety monitoring, transparent communication and stakeholder engagement to maintain consumer confidence.

Haleon plc (HLN.L): Mission and Values

• Decentralized regional model: Haleon operates through regional teams that manage operations across North America, Europe, the Middle East & Africa (EMEA), Latin America and the Asia Pacific, allowing tailored local execution while leveraging global scale.
• Workforce: Approximately 24,000 employees globally, with an emphasis on an agile, performance-focused culture and cross-functional collaboration.
• Channels: A multi-channel go-to-market approach combining retail partnerships, e-commerce and direct-to-consumer (DTC) initiatives, plus distribution through healthcare professionals and pharmacies.

• Central R&D hub: A global research & development facility in Richmond, Virginia focused on formulation development, microbiology, product stability, packaging design and consumer science to accelerate innovation across brands and categories.
• Consumer science emphasis: Consumer testing, packaging ergonomics and behavioral insights are integrated into product development to improve adherence and effectiveness.

• Manufacturing footprint: Haleon maintains manufacturing sites worldwide to support regional and global brands. The company has announced the planned closure of its Maidenhead, UK plant by 2026, with production shifting to sites in Slovakia and other manufacturing locations to optimize cost and capacity.
• Global supply chain: Raw materials are sourced across multiple geographies and finished products are distributed to more than 90 countries, supported by regional supply-chain hubs and contract manufacturers where appropriate.

• Brand-led consumer sales: Revenue is driven by a portfolio of global and regional consumer healthcare brands (science-backed OTC medicines, oral health, vitamins & supplements, respiratory and pain relief), marketed via mass retail, pharmacies and digital channels.
• Pricing & mix: Profitability depends on premiumization of brands, product mix shifts (e.g., higher-margin DTC and branded formulations) and cost-savings from manufacturing and supply-chain optimization.
• Innovation & line extensions: New SKUs, packaging innovations and clinically validated line extensions support incremental sales and encourage retailer listings and share gains.

• Annual revenue range: roughly £7-8 billion (recent fiscal years; varies by reporting period and FX).
• Geographic sales mix (approximate): Europe ~35%, North America ~25%, Asia Pacific ~20%, Latin America ~10%, Other markets ~10%.
• Distribution reach: products sold in over 90 countries, supported by regional networks and partner agreements.

• Key performance levers: market share in core categories (oral health, pain relief, vitamins), new product launches, gross margin improvement through manufacturing efficiencies and supply-chain optimization, and growth in e-commerce/DTC channels.
• Site rationalization: the Maidenhead closure (to be completed by 2026) illustrates ongoing portfolio and capacity optimization to lower unit costs and concentrate production in lower-cost, high-capacity locations (e.g., Slovakia).
• R&D productivity: cross-functional investment in Richmond, VA and regional capabilities to shorten innovation cycles and improve time-to-market for clinically differentiated products.

Haleon plc (HLN.L): How It Works

• Primary revenue drivers: sales of finished consumer healthcare products through retail, pharmacy chains, e‑commerce and institutional channels.
• Product categories: Over‑the‑Counter (OTC), Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, and Respiratory Health.
• Brand-led strategy: focus on nine power brands (e.g., Sensodyne, Panadol, Advil, Centrum, Otrivin) that deliver a disproportionate share of sales and margin.
• Geographic reach: operations and distribution in over 90 countries, leveraging regional supply chains and local marketing to scale global brands.
• Growth levers: product innovation (formulation, delivery formats, premium/specialist oral health), marketing investment, line extensions, and entry into new markets and channels.

• How revenue is captured across the value chain:
  • Product innovation and premium positioning (higher ASPs for specialist oral care and clinically backed claims).
  • High-frequency, repeat purchases for categories like VMS and pain relief.
  • Trade and retail promotions, slotting and merchandising to secure shelf space and drive volume.
  • Direct and indirect channels: pharmacies, supermarkets, e‑commerce, and healthcare professionals where applicable.
• Commercial focus: allocate marketing and R&D to power brands and high-margin segments to expand share and defend pricing.

Haleon plc (HLN.L): How It Makes Money

• Market share: 7.3% of the global OTC medicines market (2022).
• Core brands: Sensodyne, Panadol, Advil, Centrum, Otrivin - high-margin, repeat-purchase products with global recognition.
• Channels: Supermarkets, pharmacies, e-commerce, wholesalers, and emerging-market distribution partners.

• Product sales: Primary income from OTC product units sold across global markets; recurring demand for analgesics, oral care, vitamins, and cold & flu remedies.
• Pricing & mix: Margin expansion through premium brand positioning (e.g., Sensodyne) and price/mix optimization in developed markets.
• Cost & productivity: Planned £800m productivity savings over five years to boost operating margins.
• Working capital efficiency: 30% annual reduction target to free up cash and support reinvestment.
• R&D and innovation: Ongoing investment to extend current brands, develop new delivery formats and digital health adjacencies to increase lifetime customer value.
• Geographic diversification: Balanced exposure across developed and emerging markets reduces revenue volatility.

• Scale: Global brand portfolio drives distribution leverage and negotiating power with retailers and suppliers.
• Operational improvements: Supply chain efficiencies and portfolio rationalization to lower cost of goods sold.
• Digital & e-commerce: Growing direct and online retail channels to capture higher margins and consumer data.
• Sustainability as a growth enabler: Recycle-ready packaging and health inclusivity commitments to meet consumer and regulator expectations.